Key Takeaways
- • Ampersand Capital Partners closed its twelfth primary fund, AMP-26, at a $1.5 billion hard cap in less than five months after launch, achieving an oversubscribed closing with strong institutional demand.
- • The fund secured commitments from a diversified global investor base including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices, signaling robust confidence in the firm's healthcare and life sciences strategy.
- • Ampersand targets middle-market companies with $10 to $200 million in revenue and positive EBITDA through majority and minority investments, maintaining its 35-year focus on mission-critical tools and services within healthcare and life sciences.
- • The firm manages over $4 billion in assets under management and has built a track record of partnering with founders and management teams to accelerate growth across its core healthcare sectors since its 1988 founding.
- • McDermott Will & Schulte LLP provided legal counsel for the fundraise, which achieved its hard cap target ahead of schedule, reflecting strong market appetite for established healthcare-focused private equity strategies.
Summary
Ampersand Capital Partners announced on May 28, 2026, the closing of Ampersand 2026 Limited Partnership (AMP-26) at its $1.5 billion hard cap, marking a significant milestone for the Boston-based private equity firm. The oversubscribed fund reached full capitalization in less than five months following its launch, demonstrating robust institutional investor appetite for the firm's established healthcare investment strategy. This represents Ampersand's twelfth primary fund since its founding in 1988.
The fund attracted a geographically and institutionally diverse investor base, including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices. According to Ampersand Managing Partner Herb Hooper, the rapid close and oversubscription reflect "exceptional support from both existing and new investors, and their continued confidence in Ampersand's specialized investment strategy." The speed of capital deployment—achieving hard cap closure within five months—underscores sustained institutional confidence in the firm's approach to healthcare and life sciences investing.
Ampersand's investment strategy focuses on partnering with founders and management teams to build market-leading companies providing mission-critical tools and services to the innovation ecosystem within healthcare and life sciences sectors. The firm targets middle-market investments in companies with $10 to $200 million in revenue and positive EBITDA, utilizing both majority and minority investment structures. With over $4 billion in assets under management and more than 35 years of operating history, Ampersand has established itself as a trusted partner to founders and CEOs seeking growth acceleration and operational scaling within its core healthcare verticals.
The fundraise was supported by McDermott Will & Schulte LLP, which provided legal services for the transaction. The successful AMP-26 closing reinforces the continued institutional appetite for specialized healthcare-focused private equity strategies, particularly those targeting profitable middle-market operators with established revenue bases and recurring business models.
The fund attracted a geographically and institutionally diverse investor base, including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices. According to Ampersand Managing Partner Herb Hooper, the rapid close and oversubscription reflect "exceptional support from both existing and new investors, and their continued confidence in Ampersand's specialized investment strategy." The speed of capital deployment—achieving hard cap closure within five months—underscores sustained institutional confidence in the firm's approach to healthcare and life sciences investing.
Ampersand's investment strategy focuses on partnering with founders and management teams to build market-leading companies providing mission-critical tools and services to the innovation ecosystem within healthcare and life sciences sectors. The firm targets middle-market investments in companies with $10 to $200 million in revenue and positive EBITDA, utilizing both majority and minority investment structures. With over $4 billion in assets under management and more than 35 years of operating history, Ampersand has established itself as a trusted partner to founders and CEOs seeking growth acceleration and operational scaling within its core healthcare verticals.
The fundraise was supported by McDermott Will & Schulte LLP, which provided legal services for the transaction. The successful AMP-26 closing reinforces the continued institutional appetite for specialized healthcare-focused private equity strategies, particularly those targeting profitable middle-market operators with established revenue bases and recurring business models.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.